NEURO-OUTCOME OF ECMO SURVIVORS--FACTS AND PREDICTORS

本研究旨在了解脑卒中幸存者的神经学结局， 体外膜肺氧合（ECMO）。 培训方面将 提高PI在以下领域的专业知识：临床研究设计， 数据收集，生物统计学评价，管理多学科 学习和视频脑电图/神经生理学技能。 PI的目标是 成为一名全面的临床新生儿神经生理学家。 具体 临床研究目的包括： 1. ECMO中神经系统不良结局发生率的确定 幸存者 2. ECMO中神经功能结局不良的风险因素识别 幸存者 3. ECMO幸存者癫痫发生率的测定。 4. ECMO幸存者癫痫风险因素的识别， 特别是脑电图记录的新生儿癫痫发作的有效性。 所有ECMO幸存者的队列将被长期使用， 多学科临床研究的神经系统结果， 神经生理学研究（EEG）、神经学检查和神经心理学检查 试验. 将对该队列进行评价，以确定某些事件是否 (such如中风）建立了神经学结果差的高风险。 此外，其他潜在的风险因素（如胎龄， 肺部诊断等）将进行单变量检查， 多因素分析、ana和logistic回归分析。 中 类似的方式，幸存者中癫痫的发病率将是 确定并识别风险因素。 将特别注意 EEG记录的癫痫发作作为一个预测因素的重要性 后来癫痫。 ECMO治疗在美国的82个中心可用。这项研究将 提供ECMO幸存者的综合结局， 目的 本研究中产生的信息可能具有重要意义。 成本/风险/效益分析的价值，以评估这种积极的 疗法

This study seeks to understand the neurologic outcome of survivors of extracorporeal membrane oxygenation (ECMO). The training aspect will improve the PI's expertise in the following areas: clinical study design, data collection, biostatistical evaluation, managing a multidisciplinary study, and video EEG/neurophysiology skills. The PI's goals are to become a well-rounded clinical neonatal neurophysiologist. Specific clinical study aims include: 1. Determination of the incidence of poor neurologic outcome in ECMO survivors. 2. Identification of risk factors for poor neurologic outcome in ECMO survivors. 3. Determination of the incidence of epilepsy in ECMO survivors. 4. Identification of risk factors for epilepsy in ECMO survivors, especially the validity of EEG-documented neonatal seizures. A cohort of all ECMO survivors will be utilized in a long-term, multidisciplinary clinical study of neurologic outcome as measured by neurophysiologic studies (EEG), neurologic exams, and neuropsychological tests. This cohort will be evaluated to determine if certain events (such as stroke) establish high risk for poor* neurologic outcome. Additionally, other potential risk factors (such as gestational age, pulmonary diagnosis, etc) will be examined with univariate and multivariate analyses, ana and logistic regression analyses. In a similar fashion, the incidence of epilepsy in survivors will be determined and risk factors identified. Particular attention will be paid to the significance of EEG-documented seizures as a predictor for later epilepsy. ECMO therapy is available at 82 centers in the U.S.A. This study will provide a comprehensive outcome of ECMO survivors for prognostic purposes. The information generated in this study may have significant value in cost/risk/benefit analyses required to evaluate such aggressive therapy.